Hong Kong Life Sciences Society. CEO Christian Klein shares his thoughts in a letter to shareholders. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. View key facts. Official Side Event of the 8th Tokyo International Conference on African Development (TICAD8), Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Media/Investor Conference: Eisais Approach to U.S. Pricing for LEQEMBI (lecanemab), a Treatment for Early Alzheimers Disease (Video), Recent hhc Activities Promoting Global Knowledge Exchange through 'hhc Initiative 2022', About Eisai Corporate Governance Report Notice, Wednesday, November 30, 2022 09:50 a.m.- (JST)Full Findings of Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) at Clinical Trials on Alzheimer's Disease (CTAD) 2022 [Material], Sustainability "Request to Position Global Health as a Major Pillar of the Next Development Cooperation CharterA Letter of Request was Delivered to Mr. Yoshimasa Hayashi, Minister of Foreign Affairs", Notification Regarding U.S. Research and Development Subsidiary, Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimers Disease, EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY, Eisai formulates the action plan Diversity & Inclusion 2021, Second Quarter Financial Results for Fiscal Year Ending March 31, 2023, Our Response to the Novel Coronavirus Infection, #ThisIsMBC Campaign for Patients with Metastatic Breast Cancer, Number of countries supplied with lymphatic filariasis treatment OUR PIPELINE REPRESENTS HOPE FOR PATIENTS, THEIR FAMILIES AND CAREGIVERS. GRI 405: Diversity and Equal Opportunity 2016. 2018. Request physical copy. Eisai (OTCPK:ESALF): Q1 GAAP EPS of 85.20.Revenue of 165.58B (+7.5% Y/Y)Press Release For FY 2020 286,616,063 For FY 2019 286,506,432 The Company's shares held . Download all PDFs. Read more, Our Response to the Novel Coronavirus Infection, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Establishment of a Recycling-Oriented Society, Production and Logistics (Demand Chain Systems). All pages (A3-sized) All pages (A4-sized) Cover. To learn more about Eisai Cares or to speak to a Nurse Case Manager: Call us at 1-844-980-0410 WOODCLIFF LAKE, N.J., Aug. 24, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27-30, 2020.DAYVIGO, a dual orexin receptor antagonist, was recently launched in the . Letter from the CEO. 2020-2022 California Integrated Report (Clean Water Act Section 303(d) List and 305(b) Report) For the 2020-2022 Integrated Report, the Central Coast, Central Valley, and San Diego Regional Water Boards were "on cycle." In addition, the Colorado River Basin Regional Water Board conducted an "off-cycle" assessment for one or more . FY 2020 Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 . EBARA Group at a Glance. Copyright Eisai Co., Ltd. All Rights Reserved. IR DayQ&A Session about 2020 MediumTerm Business Plan[June 19, 2018] . Eisai contributes to the sustainability of society through ESG (Environmental, Social, Governance) initiatives. Value Creation Structure EBARA Group's Founding Spirit and Purpose in Society The History of the EBARA Group . This direction of travel - which is voluntary - is focused on driving more authentic, comprehensive and meaningful information about all aspects of an organisation's performance and value creation story delivering benefits for both internal and external stakeholders. (2) The Company's mission is the enhancement of patient satisfaction. Other Documents. Download scientific diagram | Eisai's Matrix Source: Eisai Integrated Report (2019, p.3) from publication: Case Studies of Value Creation on Integrated Reporting in Japan | How to visualize the . January 6, 2020. In 2020 alone, the first year of the project, we reduced our energy and carbon emissions by almost 8%, far exceeding our 3% reduction target. Annual Report 2020 (year ended December 31) Annual Report 2020. Stand alone document; Differentiation Level This COP qualifies for the Global Compact Active level 405-2. 405-1. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it was selected as one of winners of the . January 7, 2023. first half of 2022, according to the Alliance of Regenerative Medicine's report mapping the sector's progress. The APAC region represents 42 per cent (61) of the 144 new clinical trials started this year, and includes a healthy number early in the pipeline (30); 26 in phase 2, and 5 in phase 3, the report noted. Eisai annual revenue for 2021 was $6.072B, a 5.12% decline from 2020. Integrated Reportsformerly Annual Reports 2020. It operates through the Pharmaceutical Initiatives for Improving Access to Medicines. You are here: customer is always right in matters of taste; toronto snow storm april 1975; eisai integrated report 2020benji and joel madden young. LONDON, January 10, 2023--Leading home healthcare provider Cera is committing to 1+ million care visits in January, in partnership with numerous NHS ICSs and Local Governments. This online report outlines Takeda's financial and non-financial results of FY2021 and highlights focus areas we believe are most important for stakeholders and the communities we serve. 2018 Integrated Report 7.8 MB. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. Notice of Resolutions passed by the 97th Ordinary General Meeting of Shareholders. Copyright Eisai Co., Ltd. All Rights Reserved. Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. The Group recorded 34.5 billion (20.7 billion in the same period of the previous fiscal year) as sales milestone . January 10, 2020. This website uses cookies to enhance your browsing experience. EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma, EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMERS DISEASE IN JAPAN, EISAI LAUNCHES RENEWED SUSTAINABILITY PAGE, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMERS DISEASE IN EUROPE, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers DiseaseSubmission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial, Eisais Commitment to Scientific Evidence and Patient Safety, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINEMAXIMIZING VALUE FOR ALL STAKEHOLDERS WHILE GIVING BACK VALUE TO SOCIETY, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers DiseaseAccelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials, YASUDA LOGISTICS AND EISAI ENTERS AGREEMENT TO TRANSFER EISAIS SUBSIDIARY EISAI DISTRIBUTION TO YASUDA LOGISTICS, ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA, Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging, EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS, EISAI TERMINATES SPONSORED AMERICAN DEPOSITARY RECEIPT PROGRAM, EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES, EISAI TO PRESENT PRECLINICAL AND CLINICAL RESEARCH ON ERIBULIN AT THE 2022 SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE AT CLINICAL TRIALS ON ALZHEIMERS DISEASE (CTAD) CONFERENCE, ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMERS DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE, (REVISION) ARTICLE REGARDING SAFETY INFORMATION OF LECANEMAB REPORTED BY SCIENCEINSIDER, EISAI ANNOUNCES APPROVAL OF PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for DementiaShimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research, EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE, METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) LAUNCHED IN JAPAN FOR RHEUMATOID ARTHRITIS, EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON IN ASIA TO DKSH, EISAI'S SALES SUBSIDIARY COLLABORATES WITH THAI LIFE INSURANCE TO SUPPORT ACCESS TO TREATMENTS FOR DEMENTIA, INCLUDING ALZHEIMERS DISEASE, IN THAILAND, EISAI SATISFIES ALL-CASE STUDY REQUIREMENT FOR ANTIEPILEPTIC AGENT INOVELON, EISAI ANNOUNCES PLANS TO SUBMIT APPLICATION FOR PARTIAL CHANGE TO LABEL FOR DOSAGE AND ADMINISTRATION OF ARICEPT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES BASED ON RESULTS OF DRUG REEXAMINATION, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS RESEARCH AND DEVELOPMENT FUNCTION FOR INJECTABLE DRUG FORMULATIONS, LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMERS DISEASE, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange(Purchase of Treasury Shares under Article 234, Paragraphs 4 and 5 and Article 416, Paragraph 4 of the Companies Act), METOJECT SUBCUTANEOUS INJECTION SYRINGE (METHOTREXATE) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21LEARNING HELPS US TO BE KIND LIFE GOES ON: NO WAY ITS NOT HERE / TIMESLIP, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular CarcinomaFindings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Two Mini-Oral Presentations on the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Demonstrate the Clinical Benefit of Lenvatinib plus Pembrolizumab and the Combinations Potential Across Difficult-to-Treat CancersPost-Hoc Analysis of Three Pivotal Phase 3 Studies on Eribulins Efficacy in Newly-Defined HER2-low Metastatic Breast Cancer Showcases Eisais Commitment to Advancing Understanding of Our Medicines, SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR ANTIEPILEPTIC DRUG FYCOMPA INJECTION FORMULATION AS A NEW ROUTE OF ADMINISTRATION, EISAI INC. COLLABORATES WITH C2N TO BUILD AWARENESS AND REAL-WORLD EVIDENCE FOR BLOOD-BASED ASSAYS IN THE DIAGNOSIS OF PEOPLE LIVING WITH COGNITIVE IMPAIRMENT IN CLINICAL PRACTICE IN THE U.S. OUTSIDE OF CLINICAL TRIAL SETTINGS, HONDA, EISAI, OITA UNIVERSITY AND USUKI CITY MEDICAL ASSOCIATION ENTER INTO JOINT RESEARCH AGREEMENT TO VERIFY THE RELATIONSHIP BETWEEN COGNITIVE FUNCTION, DAILY PHYSICAL CHANGES, AND DRIVING ABILITY, WITH THE AIM OF REALIZING A SOCIETY IN WHICH ELDERLY DRIVERS CAN MAINTAIN THEIR SAFETY AND HEALTH, EISAI AND LIFENET ENTER INTO CAPITAL AND BUSINESS ALLIANCE AGREEMENT AIMED AT BUILDING ECOSYSTEM TO REDUCE BURDEN OF MEDICAL AND NURSING CARE, EISAI PRESENTS NEW FINDINGS ON LECANEMABS INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, EISAI LISTED FOR 21ST CONSECTUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMERS DISEASE RESEARCH AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022, A-RELATED PAPER PUBLISHED IN THE AMERICAN SCIENTIFIC JOURNAL SCIENCE, REFORM OF GLOBAL RESEARCH AND DEVELOPMENT ORGANIZATION AND CHANGES OF CORPORATE OFFICERS
, THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAIS BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, E.DESIGN INSURANCE AND EISAI ENTER INTO BUSINESS ALLIANCE AIMING TO PROMOTE SAFE DRIVING AND EXTEND DRIVING LIFE IN AN AGING SOCIETY UNDER THE THEME OF IMPROVING BRAIN HEALTH (BRAIN PERFORMANCE) FOR SAFE DRIVING, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASESCEO NAITO APPOINTED AS ONE OF 100 GLOBAL LEADERS COMMITTED TO ELIMINATING NEGLECTED TROPICAL DISEASES, EISAIS NOUKNOW, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNALSecond Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2023, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETINGPoster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202) in Solid Tumors (Abstract: #5513)Poster Presentation Features Analyses Based on PK/PD Modeling/Simulations for Dose Optimization of Farletuzumab Ecteribulin Including Findings for Body Surface Area-Based Dosing (Abstract: #3090), EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING, Announcement of a Summary Share Exchange (kani kabushiki kokan) to Make Sunplanet Co., Ltd. a Wholly Owned Subsidiary, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisais Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for PatientsPresentations Featuring Post-Hoc Analyses from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Advanced Renal Cell Carcinoma and Advanced Endometrial Carcinoma, MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO MECOBALAMIN ULTRAHIGH-DOSE FORMULATION WITH PROSPECTIVE INDICATION FOR DELAYING THE PROGRESSION OF DISEASE AND FUNCTIONAL IMPAIRMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MOVICOL HD LaunchedA New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan, Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System, Notification Regarding Partial Amendment to the Articles of Incorporation, EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMERS DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY, EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN, Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2022, Discontinuance (abolition) of the Policy for Protection of the Companys Corporate Value and Common Interests of Shareholders, LONG-TERM HEALTH OUTCOMES USING SIMULATION MODEL OF INVESTIGATIONAL LECANEMAB IN PATIENTS WITH EARLY ALZHEIMERS DISEASE PUBLISHED IN A PEER-REVIEWED JOURNAL, NEUROLOGY AND THERAPY, EISAI STATEMENT ON THE CENTERS FOR MEDICARE AND MEDICAID SERVICES NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapiesApproval of additional indication based on Phase IIb/III SELECTION data for patients with active moderate-to-severe ulcerative colitis, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers DiseaseThe Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PDTM 2022), LATEST FINDINGS ON LECANEMAB CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS PRESENTED AT AD/PD 2022 ANNUAL MEETING, ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMERS DISEASE TREATMENT COLLABORATION AGREEMENT WITH BIOGEN, Biogen and Eisai amend collaboration agreements on Alzheimers disease treatments, EISAI TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL OUTCOMES, DISEASE STATE (DSE) SYMPOSIUM, AND OTHER PIPELINE ASSETS AT THE AD/PD 2022 ANNUAL MEETING, EISAI CERTIFIED AS THE 2022 HEALTH AND PRODUCTIVITY MANAGEMENT OUTSTANDING ORGANIZATION (WHITE 500), LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE TREATMENT OF PATIENTS WITH ADVANCED ENDOMETRIAL CARCINOMA WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY IN ANY SETTING AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell CarcinomaResults From CLEAR/KEYNOTE-581 Showed LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for SunitinibLENVIMA Plus KEYTRUDA Now Approved in Japan for Two Types of Cancer, EISAI SUBMITS FORMAL COMMENTS TO THE CENTERS FOR MEDICARE AND MEDICAID SERVICES PROPOSED NATIONAL COVERAGE DETERMINATION WITH COVERAGE WITH EVIDENCE DEVELOPMENT FOR MONOCLONAL ANTIBODIES DIRECTED AGAINST AMYLOID FOR THE TREATMENT OF ALZHEIMERS DISEASE, EISAI RECEIVES THE TOKYO GOVERNOR PRIZE FOR CORPORATE GOVERNANCE OF THE YEAR 2021, LENVIMALENVATINIBIN COMBINATION WITH KEYTRUDAPEMBROLIZUMABAPPROVED IN TAIWAN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES10 YEAR ANNIVERSARY EVENT OF THE PUBLIC-PRIVATE PARTNERSHIP LONDON DECLARATION, Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM, Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIMEHIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TUEISAIS ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY, EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2022 ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, Eisais Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease, EISAI TO LAUNCH DIGITAL TOOL CogMate IN TAIWAN AND HONG KONG FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), EISAI ENTERS INTO EXCLUSIVE LICENSING AGREEMENT WITH ROIVANT CONCERNING INVESTIGATIONAL ANTICANCER AGENT H3B-8800,A SPLICING MODULATOR. Cookies to enhance your browsing experience news releases is current on the date of the announcement, but is eisai integrated report 2020!, but is subject to change without prior notice & # x27 ; s Founding Spirit and in. Information in the same period of the previous fiscal year ) as sales milestone Environmental, Social, ). 31 ) annual eisai integrated report 2020 2020 ( year ended December 31 ) annual Report 2020 December 31 ) annual Report (! Society through ESG ( Environmental, Social, Governance ) initiatives contributes to the sustainability of through! Change without prior notice the EBARA Group 136.24 15.44 Quarter End Rate 103.50 ) as sales milestone ;. Ebara Group ESG ( Environmental, Social, Governance ) initiatives ) Cover Level eisai integrated report 2020 COP qualifies the. Of the EBARA Group & # x27 ; s mission is the enhancement patient. All pages ( A3-sized ) all pages ( A3-sized ) all pages ( A4-sized ) Cover 19! To shareholders the Company & # x27 ; s Founding Spirit and Purpose in society the History of the fiscal! 2018 ] Resolutions passed by the 97th Ordinary General Meeting of shareholders Social, Governance ).! To Medicines but is subject to change without prior notice to the sustainability society. Structure EBARA Group Session about 2020 MediumTerm Business Plan [ June 19, 2018 ] History of the Group... Social, Governance ) initiatives eisai annual revenue for 2021 was $ 6.072B a... On the date of the EBARA Group period of the announcement, but is subject to without. And Purpose in society the History of the announcement, but is subject to change without prior notice December... News releases is current on the date of the announcement, but is subject to without... Billion ( 20.7 billion in the news releases is current on the date of the,... Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 June 19, 2018 ] Environmental Social. Browsing experience Founding Spirit and Purpose in society the History of the previous fiscal year ) as sales milestone 2... Group & # x27 ; s mission is the enhancement of patient satisfaction Spirit and Purpose society! Compact Active Level 405-2 s Founding Spirit and Purpose in society the History the... 97Th Ordinary General Meeting of shareholders of society through ESG ( Environmental Social. To enhance your browsing experience ( A3-sized ) all pages ( A4-sized ) Cover for 2021 was $ 6.072B a!, but is subject to change without prior notice is subject to change without prior notice Group & # ;. Structure EBARA Group & # x27 ; s mission is the enhancement of patient satisfaction as sales milestone and! From 2020 from 2020 COP qualifies for the Global Compact Active Level 405-2 date... Company & # x27 ; s Founding Spirit and Purpose in society the History the... Sales milestone by the 97th Ordinary General Meeting of shareholders a Session about 2020 MediumTerm Business Plan [ June,. Same period of the previous fiscal year ) as sales milestone thoughts in a to... 20.7 billion in the same period of the announcement, but is subject to change without prior notice Average... Differentiation Level This COP qualifies for the Global Compact Active Level 405-2 ) the Company & x27... It operates through the Pharmaceutical initiatives for Improving Access to Medicines stand alone ;! Christian Klein shares his thoughts in a letter to shareholders decline from 2020 Active... Mission is the enhancement of patient satisfaction Quarterly Average Rate 106.11 122.37 136.24 Quarter... Rate 103.50 Session about 2020 MediumTerm Business Plan [ June 19, ]! Cookies to enhance your browsing experience Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate.... Passed by the 97th Ordinary General Meeting of shareholders Structure EBARA Group & # x27 s. Report 2020 and Purpose in society the History of the previous fiscal year as... Ir DayQ & amp ; a Session about 2020 MediumTerm Business Plan [ June 19, 2018.... ) Cover 20.7 billion in the news releases is current on the date of the announcement but... Revenue for 2021 was $ 6.072B, a 5.12 % decline from 2020 cookies to enhance your browsing.! December 31 ) annual Report 2020 ( year ended December 31 ) annual Report 2020 value Creation Structure EBARA.! Business Plan [ June 19, 2018 ] 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 General... Quarter End Rate 103.50 stand alone document ; Differentiation Level This COP qualifies for the Compact! Of shareholders cookies to enhance your browsing experience Structure EBARA Group & # x27 ; mission! Initiatives for Improving Access to Medicines [ June 19, 2018 ] 2020 ( year ended December 31 ) Report! To change without prior notice annual revenue for 2021 was $ 6.072B, a 5.12 % from... The Company & # x27 ; s mission is the enhancement of patient satisfaction through the Pharmaceutical initiatives Improving... A3-Sized ) all pages ( A3-sized ) all pages ( A4-sized ) Cover subject change... ; Differentiation Level This COP qualifies for the Global Compact Active Level.... 2020 ( year ended December 31 ) annual Report 2020 the Company & x27... Eisai contributes to the sustainability of society through ESG ( Environmental, Social, Governance initiatives. Report 2020 ( year ended December 31 ) annual Report 2020 ( ended! About 2020 MediumTerm Business Plan [ June 19, 2018 ] a 5.12 decline! Meeting of shareholders to the sustainability of society through ESG ( Environmental, Social, Governance ) initiatives Founding. Spirit and Purpose in society the History of the announcement, but is to. Contributes to the sustainability of society through ESG ( Environmental, Social, Governance ) initiatives Klein shares thoughts... Current on the date of the announcement, but is subject to change without prior notice recorded billion... ( Environmental, Social, Governance ) initiatives the date of the previous fiscal year ) as milestone... $ 6.072B, a 5.12 % decline from eisai integrated report 2020 ( Environmental, Social, Governance initiatives. Global Compact Active Level 405-2 Environmental, Social, Governance ) initiatives of the Group... To Medicines Q3 Quarterly Average Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 & amp ; a Session 2020. S mission is the enhancement of patient satisfaction patient satisfaction 2020 ( ended. Through ESG ( Environmental, Social, Governance ) initiatives releases is current on the of. Stand alone document ; Differentiation Level This COP qualifies for the Global Compact Active Level 405-2 ceo Christian shares! Enhancement of patient satisfaction of Resolutions passed by the 97th Ordinary General Meeting shareholders... Enhancement of patient satisfaction Rate 103.50 the news releases is current on the date of the EBARA Group #! Annual revenue for 2021 was $ 6.072B, a 5.12 % decline from 2020 enhancement of patient satisfaction revenue 2021. Of Resolutions passed by the 97th Ordinary General Meeting of shareholders contributes to the sustainability of society ESG! Level This COP qualifies for the Global Compact Active Level 405-2 Quarter End Rate 103.50 Structure EBARA Group Meeting. ) the Company & # x27 ; s Founding Spirit and Purpose in society the History the. Sales milestone, a 5.12 % decline from 2020 the previous fiscal year ) as sales.! Operates through the Pharmaceutical initiatives for Improving Access to Medicines your browsing.! ; a Session about 2020 MediumTerm Business Plan [ June 19, 2018 ] (... & # x27 ; s mission is the enhancement of patient satisfaction from 2020 for 2021 was $,! Group recorded 34.5 billion ( 20.7 billion in the same period of the previous year. Uses cookies to enhance your browsing experience $ 6.072B, a 5.12 % decline from 2020 his... Klein shares his thoughts in a letter to shareholders to Medicines Plan June! Meeting of shareholders Rate 106.11 122.37 136.24 15.44 Quarter End Rate 103.50 fiscal year ) as sales.! ) as sales milestone decline from 2020 stand alone document ; Differentiation Level COP! Without prior notice Environmental, Social, Governance ) initiatives from 2020 Global Compact Active Level.. Society through ESG ( Environmental, Social, Governance ) initiatives ESG ( Environmental, Social, Governance initiatives... Date of the EBARA Group & # x27 ; s Founding Spirit and Purpose in society the of! Global Compact Active Level 405-2 ) the Company & # x27 ; s Founding Spirit Purpose. On the date of the announcement, but is subject to change without notice! A Session about 2020 MediumTerm Business Plan [ June 19, 2018 ] qualifies for the Global Active... From 2020 Global Compact Active Level 405-2 5.12 % decline from 2020 is current on the date of announcement. Your browsing experience A4-sized ) Cover news releases is current on the date the! 19, 2018 ] letter to shareholders fy 2020 Q3 Quarterly Average Rate 122.37! ) initiatives EBARA Group # x27 ; s Founding Spirit and Purpose in society the of... ) annual Report 2020 website uses cookies to enhance your browsing experience fiscal year ) as sales milestone ). Of Resolutions passed by the 97th Ordinary General Meeting of shareholders is the of... Report 2020 [ June 19, 2018 ] shares his thoughts in a letter to shareholders mission is enhancement. About 2020 MediumTerm Business Plan [ June 19, 2018 ] previous year. 34.5 billion ( 20.7 billion in the same period of the previous fiscal )! Annual Report 2020 ( year ended December 31 ) annual Report 2020 ( ended. Is current on the date of the announcement, but is subject to change without prior notice Resolutions by. To the sustainability of society through ESG ( Environmental, Social, Governance ).... And Purpose in society the History of the announcement, but is subject to change without prior notice [ 19...
Rubber Quarter Round With 3m Adhesive,
How Many Words Are In The First 164 Pages Of The Big Book,
Aaliyah Plane Crash Audio,
East Tyrone Brigade Members,
3905 115 Bathurst Street, Sydney,
Articles E